Physician profile
Jane E Hickney
NPI 1144393752
$6,676.37
in general payments reported to CMS, 2019-2025
27 companies · $1,547 in 2025
The $1,547 reported for 2025 was more than what 91% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,141 · 2022: $1,226 · 2023: $952 · 2024: $1,810 · 2025: $1,547.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,191 · Education: $118.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,190.86 |
| Education | $117.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $1,127.32 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $863.07 | 2021-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $803.24 | 2021-2025 | Farxiga, Lokelma |
| Otsuka America Pharmaceutical, INC. | $784.38 | 2021-2025 | Jynarque, Voyxact |
| Aurinia Pharma U.S., INC. | $468.21 | 2021-2025 | Lupkynis |
| Ardelyx, INC. | $415.99 | 2023-2025 | Ibsrela |
| Amgen INC. | $311.76 | 2021-2025 | Krystexxa, Tavneos, Repatha |
| Kowa Pharmaceuticals America, INC. | $292.06 | 2021-2022 | |
| Akebia Therapeutics INC | $267.26 | 2021-2025 | Vafseo, Auryxia |
| Calliditas Therapeutics US INC. | $219.20 | 2022-2025 | Tarpeyo |
| Lilly USA, LLC | $144.89 | 2021-2024 | Jardiance, Mounjaro |
| Vifor Pharma, INC. | $129.11 | 2021-2023 | Veltassa |
| Fresenius USA Marketing, INC. | $121.90 | 2021-2025 | Velphoro, Velphoro |
| Novo Nordisk INC | $115.28 | 2021-2025 | Ozempic |
| Mallinckrodt Hospital Products INC. | $114.83 | 2022-2024 | Acthar |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $86.55 | 2021-2023 | Krystexxa |
| Travere Therapeutics, INC. | $55.48 | 2024 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $51.78 | 2025 | Voyxact |
| Ani Pharmaceuticals, INC. | $50.48 | 2022-2025 | Purified Cortrophin Gel |
| Ucb, INC. | $43.28 | 2025 | Zilbrysq |
| Opko Pharmaceuticals, LLC | $42.19 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $41.55 | 2025 | |
| Amarin Pharma, INC. | $38.46 | 2021 | |
| Glaxosmithkline, LLC. | $28.06 | 2022 | |
| Lundbeck LLC | $25.21 | 2025 | Vyepti |
| Abbvie INC. | $17.52 | 2021 | |
| Arbor Pharmaceuticals, INC. | $17.31 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jane Hickney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.